MedTrace Logo

Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease

NCT02672306 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-04-26

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and the efficacy of (Human Umbilical Cord-Derived Mesenchymal Stem Cells) UCMSCs for patients with Alzheimer's disease (AD).

Conditions

Interventions

BIOLOGICAL

UCMSCs

Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)

BIOLOGICAL

Placebo

Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)

Sponsors & Collaborators

  • Guangzhou General Hospital of Guangzhou Military Command of PLA

    collaborator UNKNOWN

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • South China Research Center for Stem Cell and Regenerative Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-20
Primary Completion
2018-10-31
Completion
2019-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672306 on ClinicalTrials.gov